Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Cancer Treatment Reviews.
Times cited: 83
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
The Lancet Oncology.
Times cited: 402
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
New England Journal of Medicine.
Times cited: 1529